Phyo, Aung Zaw Zaw
Gonzalez-Chica, David A.
Stocks, Nigel P.
Woods, Robyn L.
Fisher, Jane
Tran, Thach
Owen, Alice J.
Ward, Stephanie A.
Britt, Carlene J.
Ryan, Joanne
Freak-Poli, Rosanne http://orcid.org/0000-0003-4072-8699
,
Funding for this research was provided by:
national institute on aging and the national cancer institute at the u.s. national institutes of health (U01AG029824, U19AG062682)
national health and medical research council of australia (334047, 1127060)
monash university (australia) and the victorian cancer agency (http://www.aspree.org.)
anz trustees, the wicking trust, and the mason foundation. (www.aspree.org)
other funding resources and collaborating organizations of the aspree study and alsop sub-study (www.aspree.org)
monash international tuition scholarship (medicine, nursing, and health sciences) and monash graduate scholarship (30072360)
finkel family foundation
national heart foundation of australia postdoctoral fellowship (101927)
national health and medical research council dementia research leader fellowship (1135727)
Article History
Accepted: 15 October 2021
First Online: 22 October 2021
Declarations
:
: The authors declare that they have no conflict of interest.
: ASPREE (ASPirin in Reducing Events in the Elderly) trial and ALSOP (ASPREE Longitudinal Study of Older Persons) sub-study are being conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and ICH-GCP guidelines and the International Conference of Harmonization Guidelines for Good Clinical Practice. ASPREE and ALSOP also follow the Code of Federal Regulations as it relates to areas of clinical research. The overall management and conduct of the ASPREE clinical trial and ALSOP sub-study are the responsibility of the ASPREE and ALSOP Steering Committee. The data of the present secondary data-analysis study were from a 5-year ASPREE clinical trial and ALSOP sub-study [Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)]. The current secondary data analysis has been approved by the Monash University Human Research Ethics Committee (Project ID: 21714) and ALSOP received ethics approval from this committee (Social ALSOP: CF11/1935–2011001094). The ASPREE trial was approved by multiple Institutional Review Boards in Australia and the U.S. (ExternalRef removed).
: This study used data from a five-year ASPREE (ASPirin in Reducing Events in the Elderly) clinical trial and ALSOP sub-study (Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)). All individual participants of the ASPREE clinical trial and ALSOP sub-study signed informed consent on participation.
: ASPREE and ALSOP are being conducted in accordance with the Declaration of Helsinki 1964 as revised in 2008, the NHMRC Guidelines on Human Experimentation, the federal patient privacy (HIPAA) law and ICH-GCP guidelines and the International Conference of Harmonization Guidelines for Good Clinical Practice. ASPREE and ALSOP also follow the Code of Federal Regulations as it relates to areas of clinical research. The overall management and conduct of the ASPREE clinical trial and ALSOP sub-study are the responsibilities of the ASPREE and ALSOP Steering Committee (ExternalRef removed).
: This study used data from a five-year ASPREE (ASPirin in Reducing Events in the Elderly) clinical trial and ALSOP sub-study [Trial Registration: International Standard Randomized Controlled Trial Number Register (ISRCTN 83772183) and clinicaltrials.gov (NCT 01038583)]. All individual participants of the ASPREE clinical trial and ALSOP sub-study signed informed consent on participation.
: All authors gave their approval for submission.
Free to read: This content has been made available to all.